NRSNW

NeuroSense Therapeutics Ltd. NRSNW

NRSNW
NeuroSense Therapeutics Ltd. BCLI
Brainstorm Cell Therapeutics Inc. IBO
Impact BioMedical Inc. AIM
AIM ImmunoTech Inc. VYNE
VYNE Therapeutics Inc. ADXN
Addex Therapeutics Ltd CDIO
Cardio Diagnostics Holdings, Inc. ALZN
Alzamend Neuro, Inc. ADIL
Adial Pharmaceuticals, Inc. VIVS
VivoSim Labs, Inc.

Net profit

EBITDA

P/E Ratio

Capitalization

Performance

Periode NRSNW BCLI IBO AIM VYNE ADXN CDIO ALZN ADIL VIVS
6M 15.38 % -13.21 % 38.01 % -11.67 % -79.08 % 16.69 % -59.76 % -63.69 % -46.14 % 66.86 %
YTD -3.23 % -67.76 % -60.84 % -87.95 % -88.63 % 14.99 % -82.78 % -78.52 % -63.58 % 66.86 %
1Y 123.55 % -68.35 % -58.69 % -89.81 % -82.55 % -17.82 % -34.09 % -84.47 % -62.51 % 66.86 %
3Y 9.49 % -98.63 % -99.84 % -94.59 % -91.34 % -44.35 % -98.53 % -99.85 % -95.17 % 66.86 %
5Y -70.30 % -99.67 % -99.84 % -98.83 % -99.73 % -96.45 % -98.47 % -99.99 % -99.18 % 66.86 %
10Y -70.30 % -98.40 % -97.59 % -99.97 % -99.98 % -96.16 % -98.47 % -99.99 % -99.62 % 66.86 %
From the beginning -70.30 % -72.73 % -97.59 % -71.10 % -99.98 % -96.16 % -98.47 % -99.99 % -99.62 % 66.86 %

Dividend